Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Total Liabilities (2021 - 2025)

Prime Medicine's Total Liabilities history spans 5 years, with the latest figure at $221.9 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 53.69% year-over-year to $221.9 million; the TTM value through Dec 2025 reached $221.9 million, up 53.69%, while the annual FY2025 figure was $221.9 million, 53.69% up from the prior year.
  • Total Liabilities reached $221.9 million in Q4 2025 per PRME's latest filing, down from $223.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $223.2 million in Q3 2025 to a low of $38.1 million in Q1 2023.
  • Average Total Liabilities over 5 years is $116.3 million, with a median of $81.0 million recorded in 2021.
  • Peak YoY movement for Total Liabilities: plummeted 79.1% in 2023, then soared 245.63% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $62.3 million in 2021, then decreased by 29.3% to $44.0 million in 2022, then soared by 38.0% to $60.8 million in 2023, then soared by 137.51% to $144.4 million in 2024, then soared by 53.69% to $221.9 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Total Liabilities are $221.9 million (Q4 2025), $223.2 million (Q3 2025), and $218.1 million (Q2 2025).